Chemical structures for localized delivery of therapeutic agents

ABSTRACT

The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.

CROSS-REFERENCES TO RELATED APPLICATIONS

This application claims priority to U.S. Application No. 61/836,800,filed Jun. 19, 2013, which is incorporated herein in its entirety.

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSOREDRESEARCH AND DEVELOPMENT

Not Applicable

BACKGROUND

Orthopaedic surgeons in the United States continue to seek improvedtherapies for the 600,000 fractures that suffer from delayed healing andthe 100,000 that become nonunions. Infected nonunions remain a challengeand frequently require staged treatment protocols. The first step isremoval of infected hardware, surgical debridement and placement ofsolid carriers preloaded with eluents (e.g. antibiotic “beads”). Thesecond step involves systemic intravenous delivery of antibiotics.Finally, the patient undergoes a second surgical procedure for possibleremoval of solid carriers, definitive surgical stabilization and localdelivery of therapeutics (e.g. recombinant human-Bone MorphogeneticProtein-2) and bone graft during surgery.

Current treatments face multiple challenges and are invasive. Theyinvolve repeated surgical approaches and are limited by the inability tomodify the therapeutics after implantation (e.g. if the cultures showresistant organisms). Systemic administration of antibiotics isproblematic secondary to the need for high blood levels to achievetherapeutic levels in the fracture environment. The side effects ofthese high serum levels require close monitoring to avoid majorcomplications. This is an issue that would benefit from improved drugdelivery methods.

This is far from the only issue faced by surgeons when it comes todelivery of therapies. Other problems include systemic intravenousdelivery (e.g. chemotherapeutic agents for cancer or intravenous painmedications), local delivery of therapeutics at the time of surgery(e.g. recombinant human-Bone Morphogenetic Protein-2 after spinefusion), and direct injection to a joint (e.g. corticosteroid injectionto a knee for osteoarthritis management). These issues would benefitfrom improved delivery of therapeutics, namely antibiotics,anti-inflammatory pain medications, bone healing modulators andchemotherapeutic agents. What is needed is a method of targeted deliveryof the therapeutic or diagnostic agent to concentrate the agent at thesite of need, thus lowering the overall dose of the therapeutic ordiagnostic agent administered to the patient. Surprisingly, the presentinvention meets this and other needs.

BRIEF SUMMARY OF THE INVENTION

In some embodiments, the present invention provides a method forselectively delivering an effective amount of a therapeutic ordiagnostic agent to a first location of a targeted organ or tissue in apatient, including the step of implanting a biocompatible solid supportin the patient at the first location of the targeted organ or tissue,wherein the solid support is linked to a first binding agent, andwherein the first location of the targeted organ or tissue cannot beselectively targeted by chemical or biological targeting agents overother locations of the targeted organ or tissue in the patient. Themethod also includes the step of administering to the patient thetherapeutic or diagnostic agent linked to a second binding agent, suchthat the first and second binding agents bind to one another uponcontact, thereby selectively delivering the effective amount of thetherapeutic or diagnostic agent to the first location of the targetedorgan or tissue in the patient.

In some embodiments, the present invention provides a method of treatinga disease or condition in a patient, including administering to thepatient a therapeutic agent linked to a first binding agent, such thatwhen the first binding agent contacts a second binding agent at the siteof the disease or condition, the first and second binding agents bind toone another forming a therapeutically effective amount of thetherapeutic agent at the site of the disease or condition, wherein theamount of the therapeutic agent administered to the patient is less thanthe therapeutically effective amount administered to the patient in theabsence of the second binding agent.

In some embodiments, the present invention provides a compositionincluding a biocompatible solid support and at least one cyclooctenelinked to the biocompatible solid support.

In some embodiments, the present invention provides a compositionincluding a therapeutic or diagnostic agent, a 1,2,4,5-tetrazine, and alinker, covalently linking the therapeutic or diagnostic agent to the1,2,4,5-tetrazine.

BRIEF SUMMARY OF THE DRAWINGS

FIG. 1 shows the preparation of a tetrazine-linked therapeutic agent.

FIG. 2 shows the preparation of the cyclooctene-linker component 9.

FIG. 3 shows absorption spectra of 0.1 mM 1 in DMF (top line at 550 nm).Addition of 0.5 equivalents of 9 resulted in a gradual decrease of theabsorption band at 540 nm. The decrease is no longer observed uponaddition of the 1.5 equivalents of 9 (bottom two lines at 550 nm),thereby suggesting that the product 9 contains no more than 33% of thecis-cyclooctene isomer.

FIG. 4 shows modification of alginate hydrogel with trans-cyclooctene(TCO).

FIG. 5 shows RP-HPLC trace of starting material tetrazine 5.

FIG. 6 shows crude radio-ITLC trace of ⁶⁴Cu-tetrazine 5 reactionmixture.

FIG. 7 shows crude radio-RP-HPLC trace of ⁶⁴Cu-tetrazine 5 reactionmixture.

FIG. 8 shows radio-RP-HPLC Trace after RP-HPLC purification of⁶⁴Cu-tetrazine 5.

FIG. 9 shows crude ITLC trace of ¹¹¹In-tetrazine 5 reaction mixture.

FIG. 10 shows crude Radio-HPLC trace of ¹¹¹In-tetrazine 5 reactionmixture.

FIG. 11 shows radio-HPLC Trace after HPLC purification of¹¹¹In-tetrazine 5.

FIG. 12 shows size exclusion HPLC spectrum indicating uptake ofradioactivity by TCO-gel.

FIG. 13 shows conjugation of the alginate-PEG-TCO and thetetrazine-PEG-DOTA-metal.

FIG. 14 shows in vitro studies with discs indicating increase in uptakeof radioactivity at experimental group.

FIG. 15 shows biodistribution of ⁶⁴Cu-tetrazine 5 at 24 hours aftertetrazine injection.

FIG. 16 shows biodistribution of ¹¹¹In-tetrazine 5 at 1 hour time pointafter tetrazine injection.

FIG. 17 shows CT images of mice receiving ⁶⁴Cu-tetrazine 5 (0.09-0.21mCi).

FIG. 18 shows CT images of mice receiving ⁶⁴Cu-tetrazine 5 (0.09-0.21mCi).

FIG. 19 shows Analysis of Imaging Data from ⁶⁴Cu-tetrazine 5 injectionby ROI and measurement of activity (absolute % of injected dose).

FIG. 20 shows Analysis of Imaging Data from ⁶⁴Cu-tetrazine 5 injectionby ROI and measurement of activity (absolute % of injected dose).

DETAILED DESCRIPTION I. General

The present invention provides a method and compositions for selectivelytargeting portions of organs or tissue that cannot be chemically orbiologically distinguished from other portions of the same organ ortissue that is not being targeted. The method involves implanting in apatient a reporter, a binding agent linked to a biocompatible solidsupport. The binding agent implanted in the patient is one-half of apair of binding agents having a very high reaction rate with each other.The reporter is implanted at a particular site of an organ or tissuethat is not chemically or biologically distinguished from other,non-targeted, sites of the same organ or tissue. The second bindingagent covalently linked to the therapeutic or diagnostic agent, theprobe, is then administered to the patient. When the two binding agentsof the reporter and probe come into contact, the reaction is rapid, anda covalent bond is formed, thus covalently linking the therapeutic ordiagnostic agent at the targeted site of the organ or tissue.Accordingly, a therapeutically effective amount of the therapeutic ordiagnostic agent can be selectively delivered to the targeted site ofthe organ or tissue in the patient.

II. Definitions

“Selectively delivering” refers to delivering a therapeutic ordiagnostic agent to a portion of an organ or tissue in need oftreatment, without targeting other portions of the organ or tissue notin need of treatment.

“Therapeutic agent” refers to an agent capable of treating and/orameliorating a condition or disease. Representative therapeutic agentsinclude, but are not limited to, paclitaxel, doxorubicin, etoposide,irinotecan, SN-38, cyclosporin A, podophyllotoxin, Carmustine,Amphotericin, Ixabepilone, Patupilone (epothelone class), vancomycin,rapamycin and platinum drugs. The therapeutic agent of the presentinvention also include prodrug forms.

“Diagnostic agent” refers to agents that assist in diagnosing conditionsor diseases. Representative diagnostic agents including imaging agentssuch as paramagnetic agents, optical probes, and radionuclides.Paramagnetic agents imaging agents that are magnetic under an externallyapplied field. Examples of paramagnetic agents include, but are notlimited to, iron particles including nanoparticles. Optical probes arefluorescent compounds that can be detected by excitation at onewavelength of radiation and detection at a second, different, wavelengthof radiation. Optical probes useful in the present invention include,but are not limited to, Cy5.5, Alexa 680, Cy5, DiD(1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine perchlorate)and DiR (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanineiodide). Other optical probes include quantum dots. Radionuclides areelements that undergo radioactive decay. Radionuclides useful in thepresent invention include, but are not limited to, ³H, ¹¹C, ¹³N, ¹⁸F,¹⁹F, ⁶⁰Co, ⁶⁴Cu, ⁶⁷Cu, ⁶⁸Ga, ⁸²Rb, ⁹⁰Sr, ⁹⁰Y, ⁹⁹Tc, ^(99m)Tc, ¹¹¹In,¹²³I, ¹²⁴I, ¹²⁵I, ¹²⁹I, ¹³¹I, ¹³⁷Cs, ¹⁷⁷Lu, ¹⁸⁶Re, ¹⁸⁸Re, ²¹¹At, Rn, Ra,Th, U, Pu and ²⁴¹Am.

“Targeted organ or tissue” refers to an organ or tissue that is beingtargeted for delivery of the therapeutic or diagnostic agent.Representative organs and tissues for targeting include those that canbe targeted by chemical or biological targeting agents, as well as thoseorgans and tissues that cannot be targeted by chemical or biologicaltargeting agents. Representative organs or tissues include bone.

“Implanting” refers to surgical implantation into the patient's body.

“Biocompatible solid support” refers a solid support material capable ofimplantation into the patient's body and supporting one of the bindingagents, as well as the therapeutic or diagnostic agent after the bindingagents conjugate. The solid support is compatible with the patient'sbody. Representative biocompatible solid supports include, but are notlimited to, hydrogels such as polysaccharide hydrogels, alginate,cellulose, chitosan, hyaluronic acid, chondroitin sulfate, heparin, andothers.

“Contacting” or “contact” refers to the process of bringing into contactat least two distinct species such that they can react. It should beappreciated, however, the resulting reaction product can be produceddirectly from a reaction between the added reagents or from anintermediate from one or more of the added reagents which can beproduced in the reaction mixture.

“Linker”, “linked” or “linking” refers to a chemical moiety that linksthe compound of the present invention to a biological material thattargets a specific type of cell, such as a cancer cell, other type ofdiseased cell, or a normal cell type. The linking can be via covalent orionic bond formation. The linking can be direct linkage between to thetwo moieties being linked, or indirectly, such as via a linker. Linkersuseful in the present invention can be up to 30 carbon atoms in length.Preferably, the linkers are 5-15 carbon atoms in length. The types ofbonds used to link the linker to the compound and biological molecule ofthe present invention include, but are not limited to, amides, amines,esters, carbamates, ureas, thioethers, thiocarbamates, thiocarbonate andthioureas. One of skill in the art will appreciate that other types ofbonds are useful in the present invention.

“Binding agent” refers to any group capable of forming a covalent bondto another binding agent in a biological environment. This is oftenreferred to as bioconjugation or bioorthogonal chemistry. Representativebinding agents include, but are not limited to, an amine and anactivated ester, an amine and an isocyanate, an amine and anisothiocyanate, thiols for formation of disulfides, an aldehyde andamine for enamine formation, an azide for formation of an amide via aStaudinger ligation, an azide and alkyne for formation of a triazole viaClick-chemistry, trans-cyclooctene (TCO) and tetrazine, and others. Thebinding agents useful in the present invention have a high reactivitywith the corresponding binding agent so that the reaction is rapid.

“Treat”, “treating” and “treatment” refers to any indicia of success inthe treatment or amelioration of an injury, pathology, condition, orsymptom (e.g., pain), including any objective or subjective parametersuch as abatement; remission; diminishing of symptoms or making thesymptom, injury, pathology or condition more tolerable to the patient;decreasing the frequency or duration of the symptom or condition; or, insome situations, preventing the onset of the symptom or condition. Thetreatment or amelioration of symptoms can be based on any objective orsubjective parameter; including, e.g., the result of a physicalexamination.

“Administering” refers to oral administration, administration as asuppository, topical contact, parenteral, intravenous, intraperitoneal,intramuscular, intralesional, intranasal or subcutaneous administration,intrathecal administration, or the implantation of a slow-release devicee.g., a mini-osmotic pump, to the subject.

“Patient” refers to animals in need of treatment, such as mammals,including, but not limited to, primates (e.g., humans), cows, sheep,goats, horses, dogs, cats, rabbits, rats, mice and the like. In certainembodiments, the patient is a human.

“Therapeutically effective amount or dose” or “therapeuticallysufficient amount or dose” or “effective or sufficient amount or dose”refer to a dose that produces therapeutic effects for which it isadministered. The exact dose will depend on the purpose of thetreatment, and will be ascertainable by one skilled in the art usingknown techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms(vols. 1-3, 1992); Lloyd, The Art, Science and Technology ofPharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999);and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003,Gennaro, Ed., Lippincott, Williams & Wilkins). In sensitized cells, thetherapeutically effective dose can often be lower than the conventionaltherapeutically effective dose for non-sensitized cells.

III. Method of Selectively Delivery of Therapeutic Agent

The present invention provides a method for selectively delivering atherapeutic agent to a location of a targeted organ or tissue in apatient. In some embodiments, the present invention provides a methodfor selectively delivering an effective amount of a therapeutic ordiagnostic agent to a first location of a targeted organ or tissue in apatient, including the step of implanting a biocompatible solid supportin the patient at the first location of the targeted organ or tissue,wherein the solid support is linked to a first binding agent, andwherein the first location of the targeted organ or tissue cannot beselectively targeted by chemical or biological targeting agents overother locations of the targeted organ or tissue in the patient. Themethod also includes the step of administering to the patient thetherapeutic or diagnostic agent linked to a second binding agent, suchthat the first and second binding agents bind to one another uponcontact, thereby selectively delivering the effective amount of thetherapeutic or diagnostic agent to the first location of the targetedorgan or tissue in the patient.

Any suitable biocompatible solid support can be used in the method ofthe present invention. For example, the biocompatible solid support canbe a hydrogel, a cross-linked polymer matrix, a metal, a ceramic, aplastic, among others. Hydrogels useful in the present inventioninclude, but are not limited to, polysaccharide hydrogels, alginate,cellulose, hyaluronic acid, chitosan, chitosin, chitin, hyaluronic acid,chondroitin sulfate, heparin, and others. Other sugar-based biomaterialsarc known in the art, such as those described in Polymer AdvancedTechnology 2014, 25, 448-460. Polymers useful as the biocompatiblesupport can include, but are not limited to, polyphosphazenes,polyanhydrides, polyacetals, poly(ortho esters), polyphosphoesters,polycaprolactones, polyurethanes, polylactides, polycarbonates,polyamides, and polyethers, and blends/composites/co-polymers thereof.Representative polyethers include, but are not limited to, Poly(ethyleneglycol) (PEG), polypropylene glycol) (PPG), triblock Pluronic([PEG]n-[PPG]m-[PEG]n), PEG diacrylate (PEGDA) and PEG dimethacrylate(PEGDMA). The biocompatible solid support can also include proteins andother poly(amino acids) such as collagen, gelatin, elastin andelastin-like polypeptides, albumin, fibrin, poly(gamma-glutamic acid),poly(L-lysine), poly(L-glutamic acid), and poly(aspartic acid).

In some embodiments, the solid support can be a hydrogel. In someembodiments, the solid support can be alginate. In some embodiments, thesolid support can be chitin. In some embodiments, the solid support canbe hyaluronic acid. In some embodiments, the solid support can bechitosin.

Any suitable binding agent can be used in the method of the presentinvention. Representative binding agents can be found in “BioconjugateTechniques” Greg T. Hermanson, 1996 and ACS Chemical Biology 2014, 9,592-605. For example, binding agents useful in the method of the presentinvention include, but are not limited to, cyclooctene, tetrazine,azide, alkyne, amine, activated ester, isocyanate, isothiocyanate,thiol, aldehyde, amide, and others. In some embodiments, the first andsecond binding agents can each independently be cyclooctene, tetrazine,azide or alkyne. In some embodiments, the first and second bindingagents can each independently be trans-cyclooctene or 1,2,4,5-tetrazine,such that one of the binding agents is trans-cyclooctene and the otheris 1,2,4,5-tetrazine.

Any suitable organ or tissue can be targeted using the method of thepresent invention. Representative organs or tissues include, but are notlimited to, bone, cartilage, ligaments, tendons, intestines, muscles,nervous system including brain, spinal cord, heart, and nerves, andothers. For example, when the organ is the heart, the method of thepresent invention can be used for cardiac repair. In some embodiments,the targeted organ or tissue is bone.

Any therapeutic or diagnostic agent can be used in the method of thepresent invention. Representative therapeutic agents include, but arenot limited to, antibiotics such as vancomycin, paclitaxel, doxorubicin,etoposide, irinotecan, SN-38, cyclosporin A, podophyllotoxin,Carmustine, Amphotericin, Ixabepilone, Patupilone (epothelone class),rapamycin and platinum drugs. Other therapeutic agents includedoxycyclin and other MMP inhibitors. In some embodiments, thetherapeutic agent can be vancomycin.

Representative diagnostic agents including imaging agents such asparamagnetic agents, optical probes, and radionuclides. Paramagneticagents imaging agents that are magnetic under an externally appliedfield. Examples of paramagnetic agents include, but are not limited to,iron particles including nanoparticles. Optical probes are fluorescentcompounds that can be detected by excitation at one wavelength ofradiation and detection at a second, different, wavelength of radiation.Optical probes useful in the present invention include, but are notlimited to, Cy5.5, Alexa 680, Cy5, DiD(1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine perchlorate)and DiR (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanineiodide). Other optical probes include quantum dots. Radionuclides areelements that undergo radioactive decay. Radionuclides useful in thepresent invention include, but are not limited to, ³H, ¹¹C, ¹³N, ¹⁸F,¹⁹F, ⁶⁰Co, ⁶⁴Cu, ⁶⁷Cu, ⁶⁸Ga ⁸²Rb, ⁹⁰Sr, ⁹⁰Y, ⁹⁹Tc, ⁹⁹mTc, ¹¹¹In, ¹²³I,¹²⁴I, ¹²⁵I, ¹²⁹I, ¹³¹I, ¹³⁷Cs, ¹⁷⁷Lu, ¹⁸⁶Re, ¹⁸⁸Re, ²¹¹At, Rn, Ra, Th,U, Pu and ²⁴¹Am. The diagnostic agents can also include chelators suchas 1,4,8,11-tetraazacyclododecane-1,4,8,11-tetraacetic acid (TETA),4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane(CB-TE2A), diethylenetriaminepentaacetice acid (DTPA) and1,4,7,10-tetra-azacyclodecanetetraacetic acid (DOTA). Other chelatorsare useful in the method of the present invention.

The method of the present invention concentrates the therapeutic anddiagnostic agent at the targeted organ or tissue. In some embodiments,the concentration of the therapeutic or diagnostic agent at the firstlocation of the targeted organ or tissue is greater than theconcentration elsewhere in the patient.

The first binding agent can be linked to the biocompatible solid supportby any suitable means known to one of skill in the art. For example, thefirst binding agent can be linked to the biocompatible solid support viaa covalent or an ionic bond. Alternatively, the first binding agent canbe intercalated in the matrix of the biocompatible solid support wherethe second binding agent can bind to the first binding agent present onthe surface of the biocompatible solid support or interior portions ofthe biocompatible solid support.

In some embodiments, the first binding agent can be covalently linked tothe biocompatible solid support. The first binding agent can covalentlybind directly to the biocompatible solid support or indirectly via theuse of a linker. Any suitable linker can be used in the presentinvention to link the binding agent to the biocompatible solid supportor the therapeutic or diagnostic agent. Representative linkers can haveabout 10 to about 100 linking atoms, and can include ethylene-oxygroups, amines, esters, amides and ketone functional groups. Otherlinkers useful in the methods of the present invention can have fromabout 10 to about 50 linking atoms, or from about 25 to about 50 linkingatoms. Representative linkers include, but are not limited to, thoseshown below:

The biocompatible solid support and therapeutic or diagnostic agent canbe modified with any suitable reporter or probe binding agent using asuitable linker, such as those show below:

When using the reporter and probe binding agents of the presentinvention, the biocompatible solid support can be modified by any meansknown to one of skill in the art. For example, covalent modificationscan esterify any carboxylic acids that are present, convert alcohols toethers or esters, or convert acids or amines to amides, as shown below:

wherein R¹, R², R³, R⁴ and R⁵ can be any suitable linker and bindinggroup. Other modifications of the biocompatible solid support caninclude carboxymethyl modification of hydroxy or amino groups.

The biocompatible solid support can be implanted by any means known toone of skill in the art.

The therapeutic or diagnostic agent can be administered in any suitableamount sufficient to treat the disease or condition the patient issuffering from. The dose, frequency and timing of such administeringwill depend in large part on the selected therapeutic agent, the natureof the condition being treated, the condition of the subject includingage, weight and presence of other conditions or disorders, theformulation being administered and the discretion of the attendingphysician. Generally, the therapeutic or diagnostic agents arcadministered in dosages ranging from about 2 mg up to about 2,000 mg perday, although variations will necessarily occur depending, as notedabove, on the disease target, the patient, and the route ofadministration. The therapeutic or diagnostic agents of the presentinvention can be administered as frequently as necessary, includinghourly, daily, weekly or monthly. The therapeutic or diagnostic agentsutilized in the pharmaceutical method of the invention are administeredat the initial dosage of about 0.0001 mg/kg to about 1000 mg/kg daily. Adaily dose range of about 0.01 mg/kg to about 500 mg/kg, or about 0.1mg/kg to about 200 mg/kg, or about 1 mg/kg to about 100 mg/kg, or about10 mg/kg to about 50 mg/kg, can be used. The dosages, however, can bevaried depending upon the requirements of the patient, the severity ofthe condition being treated, and the compound being employed. Forexample, dosages can be empirically determined considering the type andstage of disease diagnosed in a particular patient. The doseadministered to a patient, in the context of the present inventionshould be sufficient to effect a beneficial therapeutic response in thepatient over time, but is typically lower than the dose required totreat the patient without having implanted the biocompatible solidsupport that concentrates the therapeutic or diagnostic agent at theorgan or tissue requiring treatment. The size of the dose also will bedetermined by the existence, nature, and extent of any adverseside-effects that accompany the administration of a particular compoundin a particular patient. Determination of the proper dosage for aparticular situation is within the skill of the practitioner. Generally,treatment is initiated with smaller dosages which are less than theoptimum dose of the compound. Thereafter, the dosage is increased bysmall increments until the optimum effect under circumstances isreached. For convenience, the total daily dosage can be divided andadministered in portions during the day, if desired. Doses can be givendaily, or on alternate days, as determined by the treating physician.Doses can also be given on a regular or continuous basis over longerperiods of time (weeks, months or years).

IV. Method of Treating

The present invention provides a method of treating a disease orcondition in a patient using the method described above. In someembodiments, the present invention provides a method of treating adisease or condition in a patient, including administering to thepatient a therapeutic agent linked to a first binding agent, such thatwhen the first binding agent contacts a second binding agent at the siteof the disease or condition, the first and second binding agents bind toone another forming a therapeutically effective amount of thetherapeutic agent at the site of the disease or condition, wherein theamount of the therapeutic agent administered to the patient is less thanthe therapeutically effective amount administered to the patient in theabsence of the second binding agent.

Any disease or condition can be treated using the method of the presentinvention. Representative diseases or conditions include, but are notlimited to, cancer, autoimmune disorders, genetic disorders, infections,inflammation, neurological disorders, and metabolic disorders, or anycombination. In some embodiments, the disease or condition can be aninfection or an inflammation, or any combination. In some embodiments,the disease or condition can be osteomyelitis.

The disease or condition can be treated by any suitable therapeuticagent, such as those described above. In some embodiments, thetherapeutic agent can be vancomycin.

V. Compositions

The present invention also provides reporter compositions forimplantation in the patient, and probe composition for administration tothe patient and binding to the reporter composition. In someembodiments, the present invention provides a composition including abiocompatible solid support and at least one cyclooctene linked to thebiocompatible solid support.

As discussed above, the biocompatible solid support can be any suitablesolid support. In some embodiments, the solid support can be a hydrogel.In some embodiments, the solid support can be alginate.

The reporter composition of the present invention can optionally includea linker. In some embodiments, the present invention provides acomposition including a biocompatible solid support, at least onecyclooctene, and a linker, covalently linking each cyclooctene to thebiocompatible solid support. The linker can be any suitable linker, asdiscussed above. In some embodiments, the linker can have the followingstructure:

In some embodiments, the reporter composition can have the structure ofthe formula:

The present invention also provides probe compositions foradministration to the patient. The probe compositions can have a bindingagent complementary to the binding agent of the reporter composition sothat when the probe composition comes into contact with the reportercomposition, the binding agents react to form a covalent bond. In someembodiments, the present invention provides a composition including atherapeutic or diagnostic agent, a 1,2,4,5-tetrazine, and a linker,covalently linking the therapeutic or diagnostic agent to the1,2,4,5-tetrazine.

Any suitable therapeutic or diagnostic agent can be used in the probecompositions of the present invention, as discussed above.Representative therapeutic agents include vancomycin. Representativediagnostic agents include DOTA-⁶⁴Cu or DOTA-¹¹¹In. In some embodiments,the composition can have the structure:

The compounds of the present invention can be prepared by a variety ofmethods known to one of skill in the art. For example, representativeprobe compositions can be prepared as shown in FIG. 1, where Compound 1,a modified tetrazine, can be synthesized as previously described (Fox,J. M.; Hassink, M., Blackman, M.; Li, Z.; Conti, P. S.PCT/US2011/044814; WO 2012/012612). Reaction of 1 with the protectedlinker 2 under amide forming conditions results in intermediate 3.Following deprotection of the protecting group to form 4, thetherapeutic or diagnostic agent can be linked to 4, thus forming theprobe compound 5.

The reporter compositions are prepared similarly. For example, as shownin FIG. 2, Compound 6, which can be synthesized as previously described,can be linked to a protected linker under standard amide formingconditions to form 8, which is then deprotected to form 9. The reportercomposition is then formed as described in FIG. 4 by reaction of 9 withthe biocompatible solid support, alginate, for example.

The methods of making the compounds of the present invention can includeany suitable protecting group or protecting group strategy. A protectinggroup refers to a compound that renders a functional group unreactive toa particular set of reaction conditions, but that is then removable in alater synthetic step so as to restore the functional group to itsoriginal state. Such protecting groups are well known to one of ordinaryskill in the art and include compounds that are disclosed in “ProtectiveGroups in Organic Synthesis”, 4th edition, T. W. Greene and P. G. M.Wuts, John Wiley & Sons, New York, 2006, which is incorporated herein byreference in its entirety.

VI. Formulation

The compositions of the present invention can be prepared in a widevariety of oral, parenteral and topical dosage forms. Oral preparationsinclude tablets, pills, powder, dragees, capsules, liquids, lozenges,cachets, gels, syrups, slurries, suspensions, etc., suitable foringestion by the patient. The compositions of the present invention canalso be administered by injection, that is, intravenously,intramuscularly, intracutaneously, subcutaneously, intraduodenally, orintraperitoneally. Also, the compositions described herein can beadministered by inhalation, for example, intranasally. Additionally, thecompositions of the present invention can be administered transdermally.The compositions of this invention can also be administered byintraocular, intravaginal, and intrarectal routes includingsuppositories, insufflation, powders and aerosol formulations (forexamples of steroid inhalants, see Rohatagi, J. Clin. Pharmacol.35:1187-1193, 1995; Tjwa, Ann. Allergy Asthma Immunol. 75:107-111,1995). Accordingly, the present invention also provides pharmaceuticalcompositions including a pharmaceutically acceptable carrier orexcipient and the compounds of the present invention.

For preparing pharmaceutical compositions from the compounds of thepresent invention, pharmaceutically acceptable carriers can be eithersolid or liquid. Solid form preparations include powders, tablets,pills, capsules, cachets, suppositories, and dispersible granules. Asolid carrier can be one or more substances, which may also act asdiluents, flavoring agents, binders, preservatives, tabletdisintegrating agents, or an encapsulating material. Details ontechniques for formulation and administration are well described in thescientific and patent literature, see, e.g., the latest edition ofRemington's Pharmaceutical Sciences, Maack Publishing Co, Easton Pa.(“Remington's”).

In powders, the carrier is a finely divided solid, which is in a mixturewith the finely divided active component. In tablets, the activecomponent is mixed with the carrier having the necessary bindingproperties in suitable proportions and compacted in the shape and sizedesired. The powders and tablets preferably contain from 5% or 10% to70% of the compounds of the present invention.

Suitable solid excipients include, but are not limited to, magnesiumcarbonate; magnesium stearate; talc; pectin; dextrin; starch;tragacanth; a low melting wax; cocoa butter; carbohydrates; sugarsincluding, but not limited to, lactose, sucrose, mannitol, or sorbitol,starch from corn, wheat, rice, potato, or other plants; cellulose suchas methyl cellulose, hydroxypropylmethyl-cellulose, or sodiumcarboxymethylcellulose; and gums including arabic and tragacanth; aswell as proteins including, but not limited to, gelatin and collagen. Ifdesired, disintegrating or solubilizing agents may be added, such as thecross-linked polyvinyl pyrrolidone, agar, alginic acid, or a saltthereof, such as sodium alginate.

Dragee cores are provided with suitable coatings such as concentratedsugar solutions, which may also contain gum arabic, talc,polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titaniumdioxide, lacquer solutions, and suitable organic solvents or solventmixtures. Dyestuffs or pigments may be added to the tablets or drageecoatings for product identification or to characterize the quantity ofactive compound (i.e., dosage). Pharmaceutical preparations of theinvention can also be used orally using, for example, push-fit capsulesmade of gelatin, as well as soft, sealed capsules made of gelatin and acoating such as glycerol or sorbitol. Push-fit capsules can contain thecompounds of the present invention mixed with a filler or binders suchas lactose or starches, lubricants such as talc or magnesium stearate,and, optionally, stabilizers. In soft capsules, the compounds of thepresent invention may be dissolved or suspended in suitable liquids,such as fatty oils, liquid paraffin, or liquid polyethylene glycol withor without stabilizers.

For preparing suppositories, a low melting wax, such as a mixture offatty acid glycerides or cocoa butter, is first melted and the compoundsof the present invention are dispersed homogeneously therein, as bystirring. The molten homogeneous mixture is then poured into convenientsized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, and emulsions,for example, water or water/propylene glycol solutions. For parenteralinjection, liquid preparations can be formulated in solution in aqueouspolyethylene glycol solution.

Aqueous solutions suitable for oral use can be prepared by dissolvingthe compounds of the present invention in water and adding suitablecolorants, flavors, stabilizers, and thickening agents as desired.Aqueous suspensions suitable for oral use can be made by dispersing thefinely divided active component in water with viscous material, such asnatural or synthetic gums, resins, methylcellulose, sodiumcarboxymethylcellulose, hydroxypropylmethylcellulose, sodium alginate,polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing orwetting agents such as a naturally occurring phosphatide (e.g.,lecithin), a condensation product of an alkylene oxide with a fatty acid(e.g., polyoxyethylene stearate), a condensation product of ethyleneoxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partialester derived from a fatty acid and a hexitol (e.g., polyoxyethylenesorbitol mono-oleate), or a condensation product of ethylene oxide witha partial ester derived from fatty acid and a hexitol anhydride (e.g.,polyoxyethylene sorbitan mono-oleate). The aqueous suspension can alsocontain one or more preservatives such as ethyl or n-propylp-hydroxybenzoate, one or more coloring agents, one or more flavoringagents and one or more sweetening agents, such as sucrose, aspartame orsaccharin. Formulations can be adjusted for osmolarity.

Also included are solid form preparations, which are intended to beconverted, shortly before use, to liquid form preparations for oraladministration. Such liquid forms include solutions, suspensions, andemulsions. These preparations may contain, in addition to the activecomponent, colorants, flavors, stabilizers, buffers, artificial andnatural sweeteners, dispersants, thickeners, solubilizing agents, andthe like.

In another embodiment, the compositions of the present invention can beformulated for parenteral administration, such as intravenous (IV)administration or administration into a body cavity or lumen of anorgan. The formulations for administration will commonly comprise asolution of the compositions of the present invention dissolved in apharmaceutically acceptable carrier. Among the acceptable vehicles andsolvents that can be employed are water and Ringer's solution, anisotonic sodium chloride. In addition, sterile fixed oils canconventionally be employed as a solvent or suspending medium. For thispurpose any bland fixed oil can be employed including synthetic mono- ordiglycerides. In addition, fatty acids such as oleic acid can likewisebe used in the preparation of injectables. These solutions are sterileand generally free of undesirable matter. These formulations may besterilized by conventional, well known sterilization techniques. Theformulations may contain pharmaceutically acceptable auxiliarysubstances as required to approximate physiological conditions such aspH adjusting and buffering agents, toxicity adjusting agents, e.g.,sodium acetate, sodium chloride, potassium chloride, calcium chloride,sodium lactate and the like. The concentration of the compositions ofthe present invention in these formulations can vary widely, and will beselected primarily based on fluid volumes, viscosities, body weight, andthe like, in accordance with the particular mode of administrationselected and the patient's needs. For IV administration, the formulationcan be a sterile injectable preparation, such as a sterile injectableaqueous or oleaginous suspension. This suspension can be formulatedaccording to the known art using those suitable dispersing or wettingagents and suspending agents. The sterile injectable preparation canalso be a sterile injectable solution or suspension in a nontoxicparenterally-acceptable diluent or solvent, such as a solution of1,3-butanediol.

In another embodiment, the formulations of the compositions of thepresent invention can be delivered by the use of liposomes which fusewith the cellular membrane or are endocytosed, i.e., by employingligands attached to the liposome, or attached directly to theoligonucleotide, that bind to surface membrane protein receptors of thecell resulting in endocytosis. By using liposomes, particularly wherethe liposome surface carries ligands specific for target cells, or areotherwise preferentially directed to a specific organ, one can focus thedelivery of the compositions of the present invention into the targetcells in vivo. (See, e.g., Al-Muhammed, J. Microencapsul. 13:293-306,1996; Chonn, Curr. Opin. Biotechnol. 6:698-708, 1995; Ostro, Am. J.Hosp. Phar m. 46:1576-1587, 1989).

VII. Administration

The compositions of the present invention can be delivered by anysuitable means, including oral, parenteral and topical methods.Transdermal administration methods, by a topical route, can beformulated as applicator sticks, solutions, suspensions, emulsions,gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.

The pharmaceutical preparation is preferably in unit dosage form. Insuch form the preparation is subdivided into unit doses containingappropriate quantities of the compounds of the present invention. Theunit dosage form can be a packaged preparation, the package containingdiscrete quantities of preparation, such as packeted tablets, capsules,and powders in vials or ampoules. Also, the unit dosage form can be acapsule, tablet, cachet, or lozenge itself, or it can be the appropriatenumber of any of these in packaged form.

The compound of the present invention can be present in any suitableamount, and can depend on various factors including, but not limited to,weight and age of the subject, state of the disease, etc. Suitabledosage ranges for the compound of the present invention include fromabout 0.1 mg to about 10,000 mg, or about 1 mg to about 1000 mg, orabout 10 mg to about 750 mg, or about 25 mg to about 500 mg, or about 50mg to about 250 mg. Suitable dosages for the compound of the presentinvention include about 1 mg, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90,100, 200, 300, 400, 500, 600, 700, 800, 900 or 1000 mg.

The compounds of the present invention can be administered at anysuitable frequency, interval and duration. For example, the compound ofthe present invention can be administered once an hour, or two, three ormore times an hour, once a day, or two, three, or more times per day, oronce every 2, 3, 4, 5, 6, or 7 days, so as to provide the preferreddosage level. When the compound of the present invention is administeredmore than once a day, representative intervals include 5, 10, 15, 20,30, 45 and 60 minutes, as well as 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24hours. The compound of the present invention can be administered once,twice, or three or more times, for an hour, for 1 to 6 hours, for 1 to12 hours, for 1 to 24 hours, for 6 to 12 hours, for 12 to 24 hours, fora single day, for 1 to 7 days, for a single week, for 1 to 4 weeks, fora month, for 1 to 12 months, for a year or more, or even indefinitely.

The compounds of the present invention can be co-administered withanother active agent. Co-administration includes administering thecompound of the present invention and active agent within 0.5, 1, 2, 4,6, 8, 10, 12, 16, 20, or 24 hours of each other. Co-administration alsoincludes administering the compound of the present invention and activeagent simultaneously, approximately simultaneously (e.g., within about1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in anyorder. Moreover, the compound of the present invention and the activeagent can each be administered once a day, or two, three, or more timesper day so as to provide the preferred dosage level per day.

In some embodiments, co-administration can be accomplished byco-formulation, i.e., preparing a single pharmaceutical compositionincluding both the compound of the present invention and the activeagent. In other embodiments, the compound of the present invention andthe active agent can be formulated separately.

The compound of the present invention and the active agent can bepresent in the compositions of the present invention in any suitableweight ratio, such as from about 1:100 to about 100:1 (w/w), or about1:50 to about 50:1, or about 1:25 to about 25:1, or about 1:10 to about10:1, or about 1:5 to about 5:1 (w/w). The compound of the presentinvention and the other active agent can be present in any suitableweight ratio, such as about 1:100 (w/w), 1:50, 1:25, 1:10, 1:5, 1:4,1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 10:1, 25:1, 50:1 or 100:1 (w/w).Other dosages and dosage ratios of the compound of the present inventionand the active agent are suitable in the compositions and methods of thepresent invention.

VIII. Examples

All reagents and NMR solvents were purchased from Sigma-Aldrich (St.Louis, Miss.), unless otherwise noted. Compound 2 was obtained from IrisBiotech (Marktredwitz, Germany), while compound 8 was purchased fromPolypure (Oslo, Norway). DOTA-NHS ester was obtained from Macrocyclics(Dallas, Tex.). Silica gel was purchased from Silicycle (Quebec,Canada), while preparative TLC plates (20×20 cm; 1000 μm in thickness)were purchased from Analtech (Newark, Del.). Ultrapure alginates werepurchased from ProNova Biomedical (Norway). [¹¹¹In] Indium chloridesolutions was purchased from PerkinElmer (Waltham, US). [⁶⁴Cu] Copperchloride in dilute HCl was purchased from Washington University (St.Louis, Mo.) or was produced in-house by the 64Ni(p,n)64Cu nuclearreaction using an 11 MeV Siemens RDS 111 cyclotron and purified by anionexchange chromatography (Biorad AG 1-X8). Dulbecco's Phosphate BufferedSaline (DPBS) was purchased from Invitrogen Corporation (Carlsbad,Calif.).

NMR experiments were carried out in CDCl₃ or [D₆]DMSO, using a Varian400 MHz VNMRS machine. High resolution ESI mass spectrometry data wasobtained using Agilent Ion Trap LC/MSD SL at Boston University ChemicalInstrumentation Center measured either in the positive or negative.During the organic synthesis phase, an Agilent 1100 Series systemequipped with a Waters XBridge C18 Column (19×250 mm) applying agradient of water and MeCN containing 0.1% TFA was used for HPLCpurification.

During radiochemistry and for in-vivo analyses and purifications,reversed-phase HPLC was performed using a Beckman-Colter System Gold 128(Brea, Calif.) chromatography systems equipped with Jupiter Proteo C-12columns (250×4.6 mm, 4 μm, Phenomenex, Torrance, Calif.) and singlewavelength or diode array UV detectors (set to 220 & 254 nm) connectedin series to a Bioscan FlowCount photomultiplier tube (PMT) (Bioscan,Washington, D.C.). Data was analyzed using the 32 Karat software package(Beckman-Colter). Mobile phase consisted of Solvent A: 0.05%trifluoroacetic acid in water and Solvent B: 100% acetonitrile, a flowrate of 1.5 mL/min, and a linear gradient beginning at 2 min afterinjection from 9% Solvent B then increasing to 81% over a 30 min periodunless otherwise stated.

During in-vitro experiments using alginate gel, molecular sieving highperformance liquid chromatography (HPLC) was performed on a WatersBreeze chromatography system with a Waters 2487 dual absorbance detector(220 & 320 nm) and a Bioscan Flow-count radioactivity detector. APhenomenex BioSep SEC-S3000 column (7.8×300 mm) was eluted in isocratic0.1 M sodium phosphate, pH 6.8, at 1.0 mL/min.

The ⁶⁴Cu and ¹¹¹In-labeling yields were determined by radio-TLC, usingITLC-SG strips (Pall Life Sciences, Ann Arbor, Mich.) eluted with 200 mMEDTA in 0.9% aq. NaCl and performed using a Bioscan 200 imaging scanner(Bioscan, Washington D.C.). In these conditions, free radionuclidesmigrate with Rf=0.9, while radionuclides attached to tetrazine 6 remainat the origin.

PET/CT data was acquired using an Inveon Preclinical Imaging Station(Siemens Medical Solutions.

Animal Handling.

All animals were handled in accordance with a protocol approved by theUniversity of California, Davis, Animal Use and Care Committee.

Statistical Analysis.

Group variation is described as the mean±one standard deviation. Singlegroups were compared with a two-tailed unpaired t test. Groups withP<0.05 were considered significantly different. Microsoft Excel version12.8.9 was used for all statistical calculations.

Example 1. Tetrazine Modified Diagnostic Agent (5) Tert-butyl(37,41-dioxo-41-((6-(6-(pyridin-2-yl)-1,2,4,5-tetrazin-3-yl)pyridin-3-yl)amino)-3,6,9,12,15,18,21,24,27,30,33-undecaoxa-36-azahentetracontyl)carbamate (3)

Dissolved 2 (0.39 g, 0.61 mmol) in DMF (15 mL). To the stirring solutionof 2 in DMF, sequentially added 1 (0.20 g, 0.55 mmol),Benzotriazol-1-yloxytris(Demethylamino)phosphonium hexafluorophosphate(BOP) (0.25 g, 0.55 mmol) and triethylamine (0.55 g, 5.5 mmol). Thereaction mixture was stirred at room temperature, under nitrogenatmosphere for 18 h. The solvent was removed under low vacuum and thetitle product was purified by gravity silica column using a gradient ofMeOH in CH₂Cl₂ (0-10%). Yield=0.40 g (74%). The NMR spectra matched theone previously published (Rossin, R.; Verkerk, P. R.; van den Bosch, S.M.; Vulders, R. C. M.; Verel, I.; Lub, J.; Robillard, M. S. Angew.Chein. Int. Ed. 2010, 49, 3375. Mooney, 1999).

N1-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethox)ethyl)-N5-(6-(6-(pyridin-2-yl)-1,2,4,5-tetrazin-3-yl)pyridin-3-yl)glutaramide(4)

Compound 3 was dissolved in a 5:1 mixture of CH₂Cl₂:TFA (10 mL) andstirred at room temperature for 2 h. The solution turned from pink todeep red. The solvents were removed and the product was azeotroped withMeOH (2×20 mL). The crude product was carried over to the next stepwithout further purification. ¹H NMR (CDCl₃) δ 10.36 (s, 1H), 9.37 (s,1H), 9.26 (bs, 1H), 9.01 (s, 1H), 8.91 (d, J=7.8 Hz, 1H), 8.81 (d, J=8.6Hz, 1H), 8.61 (d, J=8.1 Hz, 1H), 8.39 (t, 8.0 Hz, 1H), 7.95 (t, J=5.0Hz, 1H), 7.50 (s, 1H), 6.94 (bs, 3H), 3.72-3.08 (m, 35H), 2.51 (t, J=4.6Hz, 2H), 2.36 (t, J=6.0 Hz, 2H), 1.99 (t, J=6.7 Hz, 2H), 1.26 (t, J=7.3Hz, 7H). ¹³C NMR (CDCl₃) δ 175.27, 173.06, 161.32, 161.17, 159.42 (q,J=39.5 Hz, TFA), 147.52, 145.94, 142.85, 140.89, 139.13, 138.48, 130.81,128.95, 126.65, 125.97, 115.2 (q, J=287.5 Hz, TFA), 70.13, 70.09, 70.05,69.98, 69.92, 69.88, 69.77, 69.72, 69.66, 69.55, 69.49, 69.38, 69.35,69.26, 68.82, 66.52, 46.59, 39.61, 35.63, 34.67, 29.59, 21.21, 8.38.HRMS: C₄₁H₆₆N₉O₁₃ [M+H₂O] calcd. 892.4702 (different from value listedon Data), found 892.4739.

2,2′,2″-(10-(2,40,44-trioxo-44-((6-(6-(pyridin-2-yl)-1,2,4,5-tetrazin-3-yl)pyridin-3-yl)amino)-6,9,12,15,18,21,24,27,30,33,36-undecaoxa-3,39-diazatetratetracontyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triaceticacid (5)

DOTA-NHS ester (100 mg, 0.131 mmol) was added to a solution of 4 (129mg, 0.131 mmol) and triethylamine (179 μL, 1.31 mmol) in DMF (5 mL). Thereaction mixture was stirred at room temperature for 4 h. The solventwas removed under reduced pressure. The crude product was dissolved inwater, containing 0.1% TFA (2 mL) and filtered through 0.45 μmPolyvinylidene fluoride membrane (PVDF). The title product was purifiedby preparative HPLC using a gradient of H₂O (0.1% TFA) and CH₃CN (0.1%TFA). Yield 78 mg (47%). The NMR spectra matched the one previouslypublished (Rossin, R.; Verkerk, P. R.; van den Bosch, S. M.; Vulders, R.C. M.; Verel, I.; Lub, J.; Robillard, M. S. Angew. Chem. Int. Ed. 2010,49, 3375. Mooney, 1999).

HRMS: C₅₇H₉₁N₁₃O₂₀ calcd. 1278.6503, found 1278.6580.

Example 2. Preparation of TCO Conjugate4-(((S,E)-cyclooct-4-enyloxy)methyl)-(N-(9H-fluoren-9-yl)methylcarbamate)-N-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)-ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl)benzamide(8)

Compound 7 (0.15 g, 0.58 mmol) was dissolved in CH₂Cl₂ (10 mL) in a 100mL round bottom flask. A solution of 7 (0.50 g, 0.58 mmol) in CH₂Cl₂ (10mL) was added, followed by triethylamine (0.3 mL, 2.3 mmol). Thereaction mixture was stirred for 18 h at room temperature under nitrogenatmosphere. The solvents were then removed and the title product waspurified by gravity silica column using a 1:20 MeOH:CH₂Cl₂ solution asan eluent. Yield=0.19 g (33%). ¹H NMR (CDCl₃) δ 7.75 (t, J=7.9 Hz, 2H),7.68 (d, J=7.4 Hz, 2H), 7.54 (d, J=7.3 Hz, 2H), 7.34 (d, 0.1=7.8 Hz,2H), 7.30 (d, 0.1=7.7 Hz, 2H), 7.23 (t, J=7.4 Hz, 2H), 5.65-5.39 (m,2H), 4.43 (dd, J₁=14.4 Hz, J₂=5.2 Hz, 2H), 4.32 (d, J=6.8 Hz, 2H), 4.14(t, J=6.9 Hz, 1H), 3.59-3.34 (m, 48H), 2.33-1.21 (m, 10H). ¹³C NMR(CDCl₃) δ 167.33, 156.25, 143.90, 142.96, 141.18, 135.78, 133.26,131.20, 127.54, 127.04, 126.93, 126.64, 125.01, 119.83, 74.14, 70.40,70.25, 69.81, 66.43, 50.56, 47.25, 40.08, 39.68, 34.47, 32.81, 29.78,27.56.

4-(((S,Z)-cyclooct-4-enyloxy)methyl)-N-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl)benzamide (9)

Piperidine (2.5 mL) was added dropwise to a solution of 8 (193 mg, 0.19mmol) in CH₂Cl₂ (10 mL). The resulting solution was stirred at roomtemperature for 4 h. The solvents were removed and the title product waspuried by gravity silica column using a 1:10 MeOH:CH₂Cl₂ solution as aneluent. Yield=86 mg (57%). ¹H NMR (CDCl₃) δ 7.73 (t, J=7.9 Hz, 2H),7.36-7.28 (m, 2H), 6.96 (bd, J=7.5 Hz, 1H), 5.65-5.40 (m, 2H), 5.30-5.26(m, 1H), 4.54-4.33 (m, 3H), 3.60-3.36 (m, 48H), 3.06-2.99 (m, 1H),2.40-1.44 (m, 10H). HRMS: C₄₀H₇₀N₂O₁₃ calcd. 787.4878, found 787.4938.

Example 3. Alginate Chemical Modification with 9

MVG alginate, a high G-containing alginate (M:G ratio of 40:60 asspecified by the manufacturer) were used in all of the studies. Usingpreviously described carbodiimide chemistry the carboxylic acids withinhigh M- and high G-containing alginates were modified withtrans-cyclooctene 9. All reactions were performed in 25 mL 0.1M2-(N-morpholino)ethanesulfonic (MES) acid buffer containing 0.3M NaCl atpH 6.5 with 250 mg of alginate, a concentration of 1% (w/v). 12.1 mg(0.063 mmol) of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) wasadded to the alginate to activate the carboxylic acids along the polymerchain at a 1:20 molar ratio to the uronic acid monomers of the alginate.6.9 mg (0.032) of N-hydroxysulfosuccinimide (sulfo-NHS) was added as acoreactant at a 1:2 molar ratio to EDC. The amine 9 (10 mg, 0.013 mmol)was added to the reaction in 1 mL of MES buffer, and the alginates wereallowed to react for 20 h. The modified alginates were purified withextensive dialysis (MWCO 3500) over 5 days. The alginate was thenremoved from the dialysis tubing and filtered using a 0.22 μm MilliporeSterile filters into 25 mL conical vials. Then the alginate was frozenby placing it in the fridge for 1 hr, then −20° C. freezer for 2 hr, andfinally −80° C. freezer overnight. The samples were then placed in thelyophilizer until completely dry (5-10 days) and then stored at −80° C.until needed.

When ready for use, calcium cross-linked alginate hydrogels was dilutedto a 2.5% (v/v) alginate solutions in ddH2O containing 0.25% (w/v) PBS.A sterile super-saturated calcium sulfate solution was made at aconcentration of 0.21 g CaSO4/ml ddH2O. About 0.4 ml of the slurry wasadded for every 10 ml of 2.0% alginate solution.

For in-vivo use, the alginate gel solution and the super-saturatedcalcium sulfate solution mentioned above were mixed rapidly in thesyringes through a double female connector and immediately injected intothe animal.

For in-vitro experiments, the alginate gel solution and thesuper-saturated calcium sulfate solution mentioned above were mixedrapidly through a double female connector in the syringes. Then the 2%alginate gelling solution was cast between parallel glass plates with 2mm spacers to prepare gel films. Hydrogel discs were punched out of thefilm with a hole punch (McMaster-Carr, Chicago, Ill.).

The exact same protocol was used for the ionically bonded group exceptthat trans-cyclooctene 9 was not added with EDC and sulfo-NHS, but addedat a later step, with the super-saturated calcium sulfate solution. Forthe control group no trans-cyclooctene 9 was added at any point of thesequence.

Example 4. In Vitro Experiments

Tetrazine Copper Radiolabeling. ⁶⁴Cu-chloride chloride (5-10 μL in 0.5 MHCl) was diluted with 0.1 M ammonium acetate buffer (pH 7, 50-100 μL).The DOTA-conjugated tetrazine (5) was dissolved (1.28 mg/mL) in 0.1Mammonium acetate, pH 7.0. An aliquot of 5 was combined with a suitableamount of [⁶⁴Cu] copper chloride and incubated for 10 min at roomtemperature under gentle agitation. Complete incorporation of theradionuclide was monitored by radio-TLC. After HPLC purification andevaporation of the solvents under mild heat, the radiochemical purity ofthe ⁶⁴Cu-tetrazine 5 was monitored by radio-HPLC.

For animal experiments, the ⁶⁴Cu-tetrazine solution was diluted withsterile saline. The specific activity of the ⁶⁴Cu-tetrazine 5 solutionused for in vivo experiments was typically 3.3 MCi/g.

Example 5. Tetrazine Indium Radiolabeling

¹¹¹In-chloride (5-10 μL in 0.5 M HCl) was diluted with 0.1 M ammoniumacetate buffer (pH 7, 50-100 μL). The DOTA-conjugated tetrazine (5) wasdissolved (1.28 mg/mL) in 0.1M ammonium acetate, pH 7.0. An aliquot of 5was combined with a suitable amount of [¹¹¹In] indium chloride andincubated for 10 min at 37° C. under gentle agitation. Completeincorporation of the radionuclide was monitored by radio-TLC. After HPLCpurification and evaporation of the solvents under mild heat, theradiochemical purity of the ¹¹¹In-tetrazine 5 was monitored byradio-HPLC.

For animal experiments, the ¹¹¹In-tetrazine solution was diluted withsterile saline. The specific activity of the ¹¹¹In-tetrazine 5 solutionused for in vivo experiments was typically 18 Ci/g.

Example 6. In Vitro Reactivity

Size Exclusion HPLC. Compound 9 incorporation to the alginate backbonewas quantified using radiolabeled tetrazine 5 as a proxy. Briefly, a 2%alginate gel solution was mixed with a known amount oftetrazine-radionuclide with a determined specific activity. The amountof radioactivity incorporated into the gel was determined throughsize-exclusion HPLC, whereby larger compounds (alginate gel) eluteearlier than smaller compounds.

Discs.

The reactivity of alginate-TCO was tested in PBS and mouse serum.Typically, a premade disc weighing approximately 25 μg was placed in atest tube. As a control an alginate disc untreated with TCO was used.The disc was added to a saline or serum solution containing a knownamount of compound 10 tagged with a radionuclide (either ⁶⁴Cu-tetrazine5 or ¹¹¹In-tetrazine 5). Radioactivity was measured using a Wallac 1470Wizard gamma counter (PerkinElmer, Inc.). The discs were then washed andvortex three times with 250 μL of saline and the radioactivity wasmeasure again.

Example 7. In Vivo Studies

Biodistribution Experiments.

There were two biodistribution studies done. The first one was done with⁶⁴Cu-tetrazine 5, at 26 hrs after all the scans had been performed. Thesecond biodistribution study was done with ¹¹¹In-tetrazine 5 at 3 hoursafter subcutaneous injections of alginate gels, followed by intravenousinjection of tetrazine 5.

The mice were euthanized by cervical dislocation. Organs and bodilyfluids of interest, such as urine, blood, gall bladder, liver, heart,kidneys, pancreas, spleen, lungs, stomach, small intestine, largeintestine, bladder, skin, muscle, bone, tail, brain were harvested aswell as the experimental groups (gel, TCO-gel, sTCO+gel), all werewashed with de-ionized water to remove excess blood, and weighed.Radioactivity was measured using a Wallac 1470 Wizard gamma counter(PerkinElmer, Inc.). Radioactivity uptake was presented as percentinjected dose per gram (% ID/g). All values were corrected for isotopedecay.

Example 8. Imaging Experiments

Mice received injections of one of the alginate experimental groups(control, TCO-Gel, sTCO+Gel) at a subcutaneous site (either right orleft shoulder). About two hours later, the mice received tail veininjections with ⁶⁴Cu-tetrazine 5 (0.09-0.21 mCi). At 1 h after tetrazine5 injection, the mice were anesthetized with 1%-2% isoflurane and imagedthrough the PET scanner for 30 minutes, then the CT images werecollected. Static images were collected for 15 or 30 min andcoregistered with Inveon Research Workstation software (Siemens MedicalSolutions, Memphis, Tenn.). The process was repeated at 6, 14 and 26 hrsafter initial injection of alginate). PET images were reconstructed. Thesmall-animal PET images were analyzed using the Inveon ResearchWorkshop. Regions of interest were selected from PET images using CTanatomic guidelines, and the activity associated with them was measuredwith the Inveon Research Workshop software.

Although the foregoing invention has been described in some detail byway of illustration and example for purposes of clarity ofunderstanding, one of skill in the art will appreciate that certainchanges and modifications may be practiced within the scope of theappended claims. In addition, each reference provided herein isincorporated by reference in its entirety to the same extent as if eachreference was individually incorporated by reference. Where a conflictexists between the instant application and a reference provided herein,the instant application shall dominate.

1.-18. (canceled)
 19. A composition comprising: a solid implantablebiocompatible support comprising a hydrogel, polymer, sugar basedbiomaterial, protein or poly(amino-acid), each of which may beoptionally modified; and at least one binding agent covalently linked tothe solid implantable biocompatible support via a linker, wherein the atleast one binding agent is one of a pair of binding agents capable of abioorthogonal reaction in vivo.
 20. The composition of claim 19, whereinthe solid implantable biocompatible support comprises a polysaccharidehydrogel, alginate, cellulose, hyaluronic acid, chitosan, chitin,chondroitin sulfate, or heparin, each of which may be optionallymodified.
 21. The composition of claim 19, wherein the solid implantablebiocompatible support comprises a carboxymethyl modification of hydroxyor amino groups.
 22. The composition of claim 19, wherein the solidimplantable biocompatible support is modified by esterification ofcarboxylic acids, conversion of alcohols to ethers or esters, orconversion of acids or amines to amides.
 23. The composition of claim19, wherein the solid implantable biocompatible support comprisesoptionally modified alginate.
 24. The composition of claim 19, whereinthe solid implantable biocompatible support comprises optionallymodified hyaluronic acid.
 25. The composition of claim 19, wherein thebioorthogonal reaction is a reaction between an azide and alkyne, or areaction between a trans-cyclooctene and a tetrazine.
 26. Thecomposition of claim 25, wherein the bioorthogonal reaction is areaction between a trans-cyclooctene and a tetrazine.
 27. Thecomposition of claim 19, wherein the at least one binding agentcomprises tetrazine.
 28. The composition of claim 19, wherein thecomposition is formulated in a sterile injectable preparation.
 29. Thecomposition of claim 19, wherein the reaction is in a targeted organ ortissue of a patient.
 30. The composition of claim 29, wherein thepatient is human.
 31. The composition of claim 29, wherein the targetedorgan or tissue is bone, cartilage, ligaments, tendons, intestines,muscles, nervous system, brain, spinal cord, heart, or nerves.